Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $14.4 million.

  • Adma Biologics' Capital Expenditures rose 126060.61% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 26375.64%. This contributed to the annual value of $8.2 million for FY2024, which is 7241.67% up from last year.
  • Latest data reveals that Adma Biologics reported Capital Expenditures of $14.4 million as of Q3 2025, which was up 126060.61% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Capital Expenditures peaked at $14.4 million during Q3 2025, and registered a low of $757000.0 during Q3 2023.
  • In the last 5 years, Adma Biologics' Capital Expenditures had a median value of $2.8 million in 2024 and averaged $3.3 million.
  • Per our database at Business Quant, Adma Biologics' Capital Expenditures plummeted by 7786.85% in 2023 and then skyrocketed by 126060.61% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Capital Expenditures stood at $3.7 million in 2021, then grew by 1.98% to $3.7 million in 2022, then tumbled by 68.07% to $1.2 million in 2023, then skyrocketed by 130.33% to $2.8 million in 2024, then soared by 421.15% to $14.4 million in 2025.
  • Its Capital Expenditures was $14.4 million in Q3 2025, compared to $2.4 million in Q2 2025 and $4.7 million in Q1 2025.